Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) was the target of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 56,472 shares, a decrease of 20.8% from the January 29th total of 71,276 shares. Currently, 3.3% of the shares of the stock are short sold. Based on an average daily volume of 31,172 shares, the days-to-cover ratio is presently 1.8 days. Based on an average daily volume of 31,172 shares, the days-to-cover ratio is presently 1.8 days. Currently, 3.3% of the shares of the stock are short sold.

Cadrenal Therapeutics Price Performance

NASDAQ CVKD opened at $8.49 on Monday. Cadrenal Therapeutics has a 12 month low of $4.91 and a 12 month high of $20.39. The company has a market capitalization of $19.87 million, a P/E ratio of -1.06 and a beta of 1.03. The company’s 50 day simple moving average is $7.04 and its 200 day simple moving average is $10.45.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Cadrenal Therapeutics currently has an average rating of “Hold” and an average target price of $32.00.

Insider Transactions at Cadrenal Therapeutics

In other Cadrenal Therapeutics news, CFO Matthew K. Szot sold 9,933 shares of the firm’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $6.97, for a total transaction of $69,233.01. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 26.09% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Cadrenal Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in shares of Cadrenal Therapeutics by 14.3% during the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after purchasing an additional 1,818 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in Cadrenal Therapeutics in the 3rd quarter worth about $103,000. Citadel Advisors LLC acquired a new stake in Cadrenal Therapeutics during the 3rd quarter worth about $274,000. Finally, DRW Securities LLC purchased a new stake in Cadrenal Therapeutics during the fourth quarter valued at about $171,000. 7.92% of the stock is currently owned by institutional investors and hedge funds.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.